Skip to main content
. 2017 Nov 9;9(5):5517–5528. doi: 10.18632/oncotarget.22342

Figure 2. Lipid nanoparticle anti-miR-17 was effectively delivered to the liver.

Figure 2

A. The control and anti-miR-17 drugs were equally detected in both the liver and in the tumor The concentration in the tumor was lower than in the liver (*p<0.05). B. Immunohistochemistry for control and anti-miR-17 confirmed drug delivery to both the liver and the tumor. C. Anti-miR-17 but not control de-repressed known miR-17 family mRNA targets -TGFBR2, PTPN4, CROT, in MYC-driven HCC tumors (*p<0.05, **p<0.01, ***p<0.001).